SCHEMBL469138

SCHEMBL469138

Cc1ccnc(O)c1-c1nc2cc3c(cc2[nH]1)C(=O)NC3=O

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDGFRB P09619 2/20 0.40
FGFR1 P11362 2/20 0.40
KDR P35968 2/20 0.40
AMY1A P0DUB6 4/20 0.40
NPC1 O15118 2/20 0.38
RAB9A P51151 2/20 0.38
ATM Q13315 1/20 0.38
ERAP1 Q9NZ08 1/20 0.38
METAP2 P50579 1/20 0.38
METAP1 P53582 1/20 0.38
CBFB Q13951 1/20 0.38
HDAC3 O15379 1/20 0.37
HDAC7 Q8WUI4 1/20 0.37
HDAC6 Q9UBN7 1/20 0.37
HDAC9 Q9UKV0 1/20 0.37
HPSE Q9Y251 1/20 0.35
WEE1 P30291 1/20 0.34
F2 P00734 1/20 0.34
F10 P00742 1/20 0.34
PLG P00747 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10182802 0.85 MEN1 (0.42) KDRAMY1ANPC1RAB9ACBFB
SCHEMBL469140 0.78 NPC1 (0.51) PDGFRBFGFR1KDRAMY1ANPC1
SCHEMBL441275 0.73 RHEB (0.40) KDRAMY1ANPC1RAB9ACBFB
SCHEMBL441639 0.70 RHEB (0.45) AMY1ANPC1RAB9AATMERAP1
SCHEMBL10181367 0.68 AMY1A (0.35) PDGFRBFGFR1KDRAMY1ANPC1
SCHEMBL441643 0.60 RHEB (0.40) KDRAMY1ANPC1RAB9ACBFB
SCHEMBL9831955 0.60 PDE3B (0.53) NPC1RAB9AATMKDM4EALDH1A1
SCHEMBL23794347 0.59 PPOX (0.41) NPC1RAB9AKDM4EALDH1A1MAPT
SCHEMBL2244700 0.59 AMY1A (0.63) PDGFRBFGFR1KDRAMY1ANPC1
SCHEMBL9382103 0.58 PDE4A (0.74) NPC1RAB9AATMKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120065233-A1 TYROSINE KINASE INHIBITORS GREGOR VLAD EDWARD (US) 2012-03-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120065233-A1 TYROSINE KINASE INHIBITORS ALK, ROS1, ABL1 PDGFRB 182/4885FGFR1 230/4885KDR 242/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.